October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Pharmacovigilance Safety Monitoring In Clinical Trials I've been saying this for years. Now there's a study to back it up. "The main finding of the study, that 41.6% to 71.1% of gray market peptides failed fundamental safety standards,